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Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka 565-8565, JapanChronic kidney disease is a global epidemic that affects estimated
10% of the world population. As the ﬁnal common pathway of chronic
kidney diseases, renal ﬁbrosis can result in massive destruction of nor-
mal kidney structure and subsequent impairment of the function. Acti-
vated ﬁbroblasts are recognized to be principal mediators of renal
ﬁbrosis. Unlike in physiological wound repair, where ﬁbroblast activa-
tion is spontaneously reversible, the ﬁbroblast activation associated
with renal ﬁbrosis is perpetuated, and ﬁbroblastsmaintain their activat-
ed phenotype even when cultured in vitro (Müller and Rodemann,
1991; Rodemann and Müller, 1991).
Epigeneticmodiﬁcations can cause the perpetuation of renalﬁbrosis.
Previous studies have showed a prominent role of Ras signaling path-
way in renal ﬁbrosis (Hendry and Sharpe, 2003). Hypermethylation of
RASAL1, encoding an inhibitor of the Ras protein, is associated with
the perpetuation of ﬁbroblast activation and experimental renal ﬁbrosis
(Bechtel et al., 2010). Transcriptional RASAL1 repression is associated
with ﬁbroblast activation in both physiological kidney repair and path-
ological kidney ﬁbrosis. In physiological kidney repair, reversible ﬁbro-
blast activation is associated with reversible RASAL1 suppression
without RASAL1 hypermethylation; whereas in pathological kidney ﬁ-
brosis, perpetual ﬁbroblast activation is associated with irreversible
RASAL1 expression due to RASAL1 promoter hypermethylation
(Bechtel et al., 2010). Furthermore, this hypermethylation can be in-
duced by long-term exposure to proinﬂammatory cytokines such as
TGF-β1 (Bechtel et al., 2010). Bone morphogenic protein 7, an inhibitor
of TGF-β1 signaling, normalizes the RASAL promoter hypermethylation
and successfully inhibits experimental kidney ﬁbrosis (Tampe et al.,
2014).
In their article published in this issue of EBioMedicine, Tampe et al.
demonstrated that the de-methylation of RASAL1 promoter induced
by hydralazine is associated with ameliorating effects of experimental
renal ﬁbrosis. At the mechanistic level they demonstrated that hydral-
azine erases the aberrant RASAL1 promotermethylationmark and ame-
liorates experimental ﬁbrogenesis by inducing a physiological
mechanism of Tet3-mediated hydroxymethylation and subsequent re-
placement with unmethylated CpGs.
The results add new information to our current knowledge. First, by
using transgenic mice harboring transgenes for doxycycline-inducible
RASAL1 overexpression, RASAL1 over-expression was demonstratedDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.11.005.
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broblasts in these mice with unilateral ureteral obstruction. Second,
normalization of aberrant promoter methylation through administra-
tion of 5′-azacytidine or hydralazine is associatedwith attenuated ﬁbro-
blast activation and ﬁbrogenesis in experimental renal ﬁbrosis. The key
role of RASAL1 hypermethylation in renal ﬁbrosis was further con-
ﬁrmed. Third, low dosage of hydralazine can attenuate renal ﬁbrosis in
rodent model whereas antihypertensive dosage of hydralazine cannot
do so, possibly resulting from extra activation of Hif1α. And fourth,
the levels of circulating methylated RASAL1 CpG promoter fragments
reﬂect the degree of intrarenal RASAL1 promoter methylation and the
extent of kidney ﬁbrosis in animal models and in patients, similar to in-
creased levels of methylated CpG fragments which can be detected in
cancer patients.
Studying epigenetic changes in disease is important because these
patterns of methylation are potentially reversible. This article implicat-
ed several messages which may add to clinical practice in the future.
First, hydralazine at a low dosage could be a potential treatment for
renal ﬁbrosis. And second, circulating methylated RASAL1 promoter
fragments is a possible biomarker for the severity of renal ﬁbrosis.
Several questions remain to be addressed. First, the antiﬁbrosis
effect of RASAL1 overexpression is impressive. Epigenetic drugs
available now such as azacitidine and decitabine or those currently
being researched in vitro have major limitations, including lack of
speciﬁcity and efﬁcacy (Ptak and Petronis, 2008; Cantley and
Haynes, 2013). The demethylation of hydralazine might modulate
many downstream genes such as Hif1α and possibly cause addition-
al adverse effects. In this regard, RASAL1 may be an optimal therapy
target. Second, the effect of hydralazine in RASAL1 knocked-out mice
of similar conditions remains unclear. Third, circulating methylated
RASAL1 promoter fragments in peripheral blood corresponds with
levels of intrarenal levels of RASAL1 promoter methylation and de-
gree of ﬁbrosis in kidney biopsies. However, the type of sample
used for methylation association studies for disease has been a
source of controversy. It has been suggested that epigenetic changes
that cause disease are tissue speciﬁc. Differences in methylation pat-
terns within tissues have been identiﬁed, and are larger between tis-
sues in the same individual than within the same tissue between
different individuals (De Bustos et al., 2009). Therefore, whether hy-
dralazine de-methylation occurs in all types of cells is still unknown.
And fourth, these results illustrate the importance in epigenetic con-
trol over immunity and the inﬂammatory response. The interaction
of cytokines and hypermethylation of RASAL1 needs further
investigation.the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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